Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.24 USD

53.24
3,973,139

+2.04 (3.98%)

Updated Jul 25, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Swarup Gupta headshot

Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint

Global stocks were weighed down by massive losses and heightened volatility on Wall Street last week.

    Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates

    Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.

      Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

      Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

        Biogen Halts Tysabri Development in Stroke as Study Fails

        Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

          Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

          Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

            REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

            Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

              Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?

              With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.

                The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                  Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18

                  Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.

                    Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft

                    Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.

                      Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

                      Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

                        Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?

                        With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                          While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                            Sanghamitra Saha headshot

                            Top and Flop ETFs of January 2018

                            Inside the best and worst-performing ETFs of January.

                              Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

                              Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

                                Company News For Jan 30, 2018

                                Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO

                                  Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B

                                  Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.

                                    Sanghamitra Saha headshot

                                    Biotech ETF (XBI) Hits New 52-Week High

                                    This biotech ETF hit a new 52-week high. Are more gains in store for this fund?

                                      Swarup Gupta headshot

                                      Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ

                                      The government shutdown in the United States guided stocks across Europe and Asia last week.

                                        Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat

                                        Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

                                          Tirthankar Chakraborty headshot

                                          Play Biotech Buyout Frenzy With These 2 Solid Funds

                                          More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas

                                            Stock Market News For Jan 23, 2018

                                            Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown.

                                              Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                                              Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                                                Tirthankar Chakraborty headshot

                                                Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

                                                More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.

                                                  Arpita Dutt headshot

                                                  Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?

                                                  Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?